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Articular cartilage contains a subpopulation of tissue-specific progenitors that are an ideal cell type for cell
therapies and generating neocartilage for tissue engineering applications. However, it is unclear whether the
standard chondrogenic medium using transforming growth factor beta (TGFb) isoforms is optimal to differ-
entiate these cells. We therefore used pellet culture to screen progenitors from immature bovine articular
cartilage with a number of chondrogenic factors and discovered that bone morphogenetic protein-9 (BMP9)
precociously induces their differentiation. This difference was apparent with toluidine blue staining and con-
firmed by biochemical and transcriptional analyses with BMP9-treated progenitors exhibiting 11-fold and
5-fold greater aggrecan and collagen type II (COL2A1) gene expression than TGFb1-treated progenitors.
Quantitative gene expression analysis over 14 days highlighted the rapid and phased nature of BMP9-induced
chondrogenesis with sequential activation of aggrecan then collagen type II, and negligible collagen type X
gene expression. The extracellular matrix of TGFb1-treated progenitors analyzed using atomic force micros-
copy was fibrillar and stiff whist BMP9-induced matrix of cells more compliant and correspondingly less
fibrillar. Polarized light microscopy revealed an annular pattern of collagen fibril deposition typified by TGFb1-
treated pellets, whereas BMP9-treated pellets displayed a birefringence pattern that was more anisotropic.
Remarkably, differentiated immature chondrocytes incubated as high-density cultures in vitro with BMP9
generated a pronounced anisotropic organization of collagen fibrils indistinguishable from mature adult artic-
ular cartilage, with cells in deeper zones arranged in columnar manner. This contrasted with cells grown with
TGFb1, where a concentric pattern of collagen fibrils was visualized within tissue pellets. In summary, BMP9 is
a potent chondrogenic factor for articular cartilage progenitors and is also capable of inducing morphogenesis of
adult-like cartilage, a highly desirable attribute for in vitro tissue-engineered cartilage.
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Introduction
Stem cell therapies have been used in numerous studiesin attempts to repair cartilage lesions, but thus far, no
solution has been able to regenerate the full adult structure of
this tissue [1]. The most obvious route to successful cell
therapies lies in understanding and mimicking endogenous
growth and developmental processes, either to grow cartilage
in vitro or endow implanted cells with sufficient cues to
differentiate and develop functional repair tissue. Central to
achieve these objectives is the use of progenitor cells re-
ceptive to specific instructive cues as well as the use of well-
defined differentiation factors to drive the generation of
neocartilage [2,3].
Cartilage lesions are a common occurrence during ex-
ploratory knee arthroscopic surgery with a reported preva-
lence of 65% [4]. If these lesions are not repaired they may
over time progress to diffuse osteoarthritis [5]. Their treat-
ment remains difficult because intrinsic repair mechanisms
are inadequate mainly due to the avascular nature of
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cartilage tissue and the inability of resident chondrocytes to
mobilize and direct repair [6,7]. Cell transplantation and
subchondral bone stimulation [8] have been developed to
repair localized lesions [9], but crucially neither technique can
significantly reduce the medium and long-term risk of patients
developing osteoarthritis [10,11]. In a 15-year follow-up
study, Knutsen et al. found that 57% of patients treated with
cell transplantation and 48% of patients treated by micro-
fracture had radiographic signs of early osteoarthritis [11].
In contrast, osteochondral allografting is a highly effec-
tive surgical technique to repair large >2 cm2 cartilage de-
fects in synovial joints [12,13]. Cartilage and adjoining bone
from donors are transplanted to areas in recipients requiring
resurfacing with the aim of restoring normal joint function.
The principal advantages of allotransplantation are the use
of structurally intact hyaline cartilage and bone with no
concurrent morbidity as would be the case for autografting.
Clinical studies using cartilage allografts have showed fa-
vorable outcomes, with graft survival as high as 95% at
5 years and 85% at 10 years [14]. The limitations of allo-
grafting are the availability and storage of donor cartilage,
with storage beyond 21 days causing a significant reduction
in cellular viability that impact graft quality and survival
[15]. Tissue engineering has the potential to fulfill the in-
creasing demand for allografts through the use of expand-
able cell sources capable of maintaining chondrogenic
potency to generate functional hyaline neocartilage.
Donor chondrocytes from recipients cannot be used to repair
larger cartilage defects because they undergo dedifferentiation
and progressively lose the capacity to redifferentiate after 4–5
population doublings [16]. Consequently, the size of cartilage
lesions that can be repaired, typically requiring concentrations
of several million cells per cm2, is also limited [17]. To
overcome this hurdle, adult mesenchymal stem cells (MSCs)
such as bone marrow-derived stromal cells with the capacity to
undergo chondrogenic differentiation have been used for cell
therapy either by autologous implantation into defects [18] or
through marrow stimulation through drilling the subchondral
bone plate [8]. Marrow-derived MSCs generate a transient
fibrocartilagenous template with biomechanical deficits that
compromise cell survival in the adult joint [19]. More detailed
examination of marrow-derived MSC function suggests that
their therapeutic effects are mediated through paracrine effects
on recruited cells or coimplanted chondrocytes [20,21].
Therefore, the discovery of tissue-specific progenitor-like cells
in articular cartilage with the ability to generate the cell
numbers required for cell therapies and tissue engineering is of
great significance [22,23].
Articular cartilage-derived chondroprogenitors were first
detected as bromodeoxyuridine label retaining cells in the
superficial zone of fetal marsupial articular cartilage [23,24].
Subsequently, cells with colony-forming ability were iso-
lated from postnatal immature bovine cartilage that fulfilled
the minimal requirements to be classified as mesenchymal
progenitors; exhibiting plastic adherence, CD90+, CD105+,
CD73+, CD166+, CD34-, and CD45- antibody reactivity,
multipotential phenotypic plasticity, and the ability to home
joint tissues [22,25]. Articular cartilage-derived chon-
droprogenitors maintain sex determining region Y-box 9
(SOX9) expression and telomere length following extensive
culture expansion, accounting for their ability to undergo
chondrogenic redifferentiation following more than 30
population doublings [26]. Critically, studies have found
runt-related transcription factor-2 (RUNX2) and collagen
type X, markers of terminally differentiated epiphyseal
chondrocytes are absent or expressed at negligible levels in
articular chondroprogenitors, restricting their differentiation
to the production of hyaline-like cartilage [27].
Defining the optimal pathways for chondrogenic differ-
entiation and organized extracellular matrix production of
tissue specific chondroprogenitors is therefore an important
objective for tissue engineering cartilage and developing
effective cell therapies. While chondrogenesis of epiphyseal
chondroblasts and MSCs has been extensively described,
and shown to be induced in medium containing transform-
ing growth factor beta-1 (TGFb1), dexamethasone, ascor-
bate, and insulin [28], there have been no comparable
studies to determine the optimal chondrogenic medium for
articular chondroprogenitors. TGFb stimulates chondrogen-
esis in articular progenitors, although cartilage production is
principally confined to the periphery of high-density pellet
cultures, indicating a lack of potency [26].
The unique developmental history of articular chondro-
progenitors led us to hypothesize that there are more potent
chondrogenic factors for this cell type. Therefore, to deter-
mine the optimal chondrogenic medium for articular chon-
droprogenitors, we screened cells against a panel of known
chondrogenic factors using high-density pellet culture as a
means to analyze their potency.
Materials and Methods
Chondroprogenitor isolation
Articular cartilage tissue was harvested from freshly ob-
tained healthy bovine metacarpophalangeal (MCP) joints
(Cig Calon Cymru). Swansea University is registered for use
of animal by-products as required under the requirements of
Article 23 (EC) No, 1069/2009, and the work carried out in
this study using these products was following institutional
approval. Cartilage was removed from MCP joints of im-
mature 7-day-old steers under sterile conditions and washed
in Dulbecco’s modified Eagle’s medium (DMEM; Gibco)
before sequential digestion with pronase (Roche) at 70 U/
mL (0.2% w/v) in DMEM for 2 h, with the solution decanted
and then medium added containing DMEM, 10 mM HEPES
pH 7.4, 50mg/mL gentamicin, 1% fetal bovine serum (FBS)
with collagenase from Clostridium histolyticum (Sigma) at
300 CDU/mL (0.04% w/v) for 16 h, using a tube rotator or
roller (Miltenyi Biotec) at 37C and 5% CO2. Tissue digests
were passed through a gravity driven nylon 40mm cell
strainer (Corning) to generate a single cell suspension.
Chondroprogenitor isolation was performed by differential
adhesion of chondrocytes to plastic six-well plates (Greiner)
that were precoated with 10mg/mL of fibronectin (0.1% so-
lution from bovine plasma; Sigma) in phosphate-buffered sa-
line (PBS, pH 7.4) with 1 mM MgCl2 and 1 mM CaCl2 for 24 h
at 4C. Approximately 1,000 cells per well in 1.5 mL DMEM
were incubated for 20 min on the fibronectin-coated plates at
37C in a CO2 incubator, after which, nonadherent cells were
removed and 3 mL of standard culture medium, DMEM (1 g/L
glucose), 50mg/mL ascorbic acid-2-phosphate, 10 mM
HEPES pH 7.4, 1 mM sodium pyruvate, 2 mM l-glutamine,
and 10% FBS and 50mg/mL gentamicin added to each well.
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After 6 days of culture, well-spaced cell colonies of more than
32 cells, therefore excluding transit-amplifying cells, were
isolated using sterile cloning rings (Sigma) using trypsin/
ethylenediaminetetraacetic acid (EDTA) and transferred to
six-well plates for culture expansion in standard culture me-
dium. Unexpanded freshly isolated full-depth chondrocytes
used for differentiation assays using the same basal chondro-
genic medium as described below were from the same source
and used following tissue digestion and cell straining.
Chondroprogenitor differentiation
Basal medium for chondrogenic differentiation was com-
posed of DMEM/F12 nutrient mix (1:1 with GlutaMAX,
17.25mg/L l-proline, 3.151 g/L glucose; Cat. No. 31331-028;
Gibco), supplemented with 10% heat-inactivated (60C for
45 min) FBS, 100mg/mL L-ascorbic acid 2-phosphate, 1%
insulin-transferrin-selenium (ITS-X; Thermo Fisher Scien-
tific), 10 mM HEPES pH 7.4, and 50mg/mL gentamicin.
Chondrogenic factors used in this study are listed with the
final concentration used in pellet culture shown in brackets;
chelerythrine chloride (CCl), a cell-permeable inhibitor of
protein kinase C (0.66mM), dibutyryl-cAMP (db-cAMP) a
cell-permeable cyclic AMP analog that activates cAMP-
dependent protein kinases (0.5 mM; Bio-Techne Ltd.), conca-
navalin A from Canavalia ensiformis (3mg/mL), C-natriuretic
peptide (CNP; 0.1mM), ethanol (1.5% v/v; all Sigma-Aldrich),
TGFb1/2/3 (10 ng/mL), and bone morphogenetic protein
(BMP) 2/9 (100 ng/mL; all PeproTech EC, Ltd.). For three-
dimensional pellet culture, individual chondroprogenitor
clones between 22 and 27 population doublings cells were
trypsinized and 5 · 105 cells were added to a sterile Eppendorf
tubes in 1000mL basal chondrogenic medium. The cell sus-
pension was then centrifuged at 315 g for 5 min at room tem-
perature to enable pellet formation, then incubated at 37C and
5% CO2. After 24 h, cell pellets were gently aspirated with
surrounding medium from the Eppendorf surface using a pi-
pette to facilitate pellet rounding. Pellets were incubated with
fresh medium every 72 h until the end of the culture period [29].
For differentiation on two-dimensional plastic, individual
chondroprogenitor lines were seeded onto six-well dishes at a
concentration of 1 · 105 cells per well in standard culture me-
dium. Each culture plate was then incubated at 37C and 5%
CO2 until the well was 80% confluent, upon which the medium
was aspirated and 3 mL of prewarmed chondrogenic medium
with or without growth factor added. The plate was then in-
cubated at 37C and 5% CO2 and medium changed once until
analysis at 4 days posttreatment.
RNA extraction
Pellets. Stored frozen pellets were thawed and lysis
buffer RLT added (RNAEasy kit; Qiagen). Pellets were then
mechanically homogenized for 30 s using a TissueRuptor
device (Qiagen) using sterile probes. Total RNA was ex-
tracted using RNeasy columns with a DNase1 on-column
digest as per manufacturer’s instructions.
Reverse transcription-quantitative polymerase chain reac-
tion. Complementary DNA (cDNA) was synthesized using
*100 ng total RNA using standard methods. Quantitative
polymerase chain reaction (qPCR) was performed using a
Bio-Rad CFX96 thermal cycler using 25mL reaction volumes
in 96-well plates (Bio-Rad). Each reaction contained 3.5 mM
MgCl2, 200mM dNTPs, 0.3mM forward and reverse primers,
0.025 U/mL Taq polymerase, and SYBR Green (GoTaq qPCR
Master mix; Promega) with programmed reaction conditions
of 1 cycle of 95C for 10 min, 40 cycles of 95C for 30 s,
55C for 30 s, 72C for 1 min, and 1 cycle of 72C for 5 min
and then 4C. Absolute values for gene expression were
calculated from standard curves generated using cloned and
sequence-verified, serially diluted, plasmid template DNA.
Primer sequences used for reverse transcription-qPCR) have
been previously published [30–32].
Biochemical compositional analysis
Before biochemical analyses, frozen cell pellets were
thawed and solubilized by incubation in papain digestion
buffer (20 mM NaAc pH 6.8, 1 mM EDTA pH 8.0, 2 mM
dithiotheitol, and 300 mg/mL papain from Papaya latex;
Sigma) at 60C for 1 h. The Quant-iT PicoGreen dsDNA
Assay Kit (Thermo Fisher Scientific) was used to measure
DNA content using 50 mL volume of papain digested pellet
according to the manufacturer’s protocol and measured us-
ing a FLUOstar Omega plate reader (BMG Labtech). Data
were compared to a linear standard curve (0–20 mg/mL)
made using calf thymus DNA. To calculate cell number,
DNA values were divided by 7.7 pg, the approximate weight
of the bovine genome [33]. For sulfated glycosaminoglycan
(sGAG) measurements, 20 mL of papain digested pellet
sample was added to 200mL of DMMB reagent (16 mg/L
dimethylmethylene blue, 3 g polyvinyl alcohol 30–70 kDa,
3.04 g glycine, 2.37 g NaCl, and 95 mL 0.1 M HCl) in a
96-well plate before shaking for 5 s. The concentration of
sGAG in each sample was determined by spectrophoto-
metric measurement of absorbance at 525 nm and compared
against a standard curve of shark chondroitin-4-sulphate
(0–40mg/mL; Sigma). Collagen content in pellets was deter-
mined using an assay to measure hydroxyproline in papain
digested samples and comparing values against a standard
curve of hydroxyproline (0–100mg/mL).
Histological analysis
Cell pellets were washed with PBS then fixed in 10%
neutral buffered formyl saline (NBFS) for 12 h at 4C, then
processed for wax embedding. sGAG deposition was ob-
served by using the metachromatic dye toluidine blue at 1%
aqueous concentration for 60 s. To visualize collagen con-
tent and fibril alignment, rehydrated sections were stained in
0.1% w/v picrosirius red in saturated picric acid for 30 min.
Immunohistochemistry
Formalin-fixed paraffin-embedded samples were sectioned
to a thickness of 5mm before immunohistochemical labeling.
Sections were dewaxed in Histo-Clear (National Diagnostics)
and rehydrated through an ethanol gradient before being
brought to deionized water. Antigen retrieval was performed in
two stages; an overnight incubation at 65C in a pH 9 10 mM
Tris, 1 mM EDTA, 0.05% Tween-20 buffer solution, followed
by incubation with 1 mg/mL hyaluronidase (bovine testes;
Sigma) in phosphate-buffered saline (PBS) buffer at 37C for
1 h. Sections were blocked using horse serum (2.5%; Vector
Laboratories) for 30 min. Labeling was performed against
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aggrecan [1-C-6, Developmental Studies Hybridoma Bank
(DSHB)], collagen type I (C2456; Sigma), and collagen type II
(II6B3, DSHB). Primary antibodies were diluted 1:10 for ag-
grecan and collagen type II and 1:2,000 for collagen type I, in
PBS Tween-20 (0.05%). Primary antibody detection was per-
formed using the RTU biotinylated pan-specific antibody, RTU
streptavidin/peroxidase complex and ImmPACT NovaRED
Peroxidase Substrate (Vector Laboratories), according to
manufacturers’ instructions. Sections were counterstained with
Meyer’s hematoxylin (TCS Biosciences) and mounted using
DPX Mounting Medium (Electron Microscopy Sciences).
Atomic force microscopy
Chondroprogenitor cell monolayer cultures were imaged
and analyzed using quantitative nanomechanical mapping
(QNM) and force volume (FV) to assess changes in mor-
phological and nanomechanical phenotype between the
different populations at expansion stage and under differ-
entiation conditions. Imaging experiments were performed
using a Bioscope Catalyst (Bruker) instrument in either
QNM or FV mode. High aspect ratio silicon probes, MLCT-
D (Bruker), were used for the experiments with a spring
constant of 0.03 N/m and a cantilever calibrated using in
house manufacturer protocols before each experiment. Cells
were imaged alive in DMEM without phenol red (Gibco)
media, at 37C. Care was taken to avoid the generation of
imaging artefacts throughout. At least 6 cells per sample
were analyzed taking 25 FV curves per cell in a 2.5 mm2 area
in 30 min not to lose the phenotype or adherence of the cells.
A 1 mm ramp size was applied to the sample with a force of
500 pN, the ramp rate was 1.03 Hz with constant forward
and reverse tip velocity of 2.06 mm/s. When imaging in
QNM mode, peak force amplitude and frequency were set at
500 nm and 0.25 kHz, respectively. The scan rate was 0.5 Hz
and the 5.05 mm/s tip velocity, applying a force between 1
and 0.5 nN with feedback gain of 1.000.
Statistical analyses
All statistical approaches were performed using SPSS
software version 19.0 for the windows operating system. All
data sets were first analyzed for normality using the An-
derson Darling test. Statistical significance was calculated
using one-way analysis of variance. Post hoc analysis was
performed using Tukey’s honestly significant difference
method. All statistical significance threshold values are
P < 0.05, unless otherwise stated in the text.
Results
Articular cartilage progenitors from immature cartilage
were cultured as high-density cell pellets for 21 days in the
presence of minimal chondrogenic culture medium that was
supplemented with previously characterized chondrogenic
factors, TGFb1–3 (10 ng/mL), BMP 2/9 (100 ng/mL),
dexamethasone (Dex), CNP, db-cAMP, concavalin-A
(ConA), ethanol (EtOH), and CCl at concentrations previ-
ously shown to induce differentiation in receptive mesen-
chymal cells [34–43]. Histologic examination of toluidine
blue-stained sections of cartilage pellets showed an in-
creasing gradation in size and staining intensity from etha-
nol to BMP9-treated chondroprogenitors (Fig. 1). Only
BMP9-treated chondroprogenitors showed uniform deep
purple toluidine blue staining throughout the pellet depth,
with the other factors showing variegated staining of pellets
due either to the lack of sulfated proteoglycan or to the
metachromatic nature of the dye, where reduced staining is
visualized as a blue color.
Quantification of sGAG content using the DMMB assay
normalized to DNA content revealed a 6-fold increase in
sGAG in BMP9 pellets compared to minimal medium alone
(P < 0.01) and 2.3-fold greater accumulation of sGAG than
TGFb1-treated pellets (P < 0.01) (Fig. 2A). Other than
BMP9, only dexamethasone 2.4-fold, TGFb1 2.8-fold, and
db-cAMP 3.3-fold showed significantly increased sGAG
content (P < 0.01) compared to pellets cultured in minimal
medium. When hydroxyproline content was measured in
pellets, TGFb2 3.4-fold, TGFb3 3.4-fold, db-cAMP 5.8-
fold, TGFb1 7.8-fold, and BMP9 11.5-fold-treated pellets
showed a greater deposition of collagen compared to pellets
cultured in minimal medium (P < 0.01) (Fig. 2B). Analysis
of aggrecan (ACAN) and collagen type II (COL2A1) gene
FIG. 1. Toluidine blue-stained sections of chondroprogenitor pellets grown as high-density pellet cultures. Pellets of 5 · 105
cells were grown in minimal chondrogenic medium (Con) or supplemented with EtOH, CCl, ConA, CNP, BMP2/9, TGFb1–3,
dexamethasone (Dex), and dc-AMP. Pellets are ordered according to the quantity of sGAG normalized to DNA content (Fig. 2A).
Representative images of three independent experiments. Scale bar equals 500mm. BMP, bone morphogenetic protein; CCl,
chelerythrine chloride; CNP, C-natriuretic peptide; ConA, concavalin-A; dc-AMP, dibutyryl cyclic adenosine monophosphate;
EtOH, ethanol; sGAG, sulfated glycosaminoglycan; TGFb, transforming growth factor beta. Color images are available online.
4 MORGAN ET AL.
expression in pellets led to broadly similar changes with
BMP9 pellets showing 33-fold greater ACAN gene ex-
pression compared to pellets in minimal medium (P < 0.01)
and 10.6-fold more than in TGFb1 pellets (P < 0.01)
(Fig. 2C). COL2A1 gene expression was similarly 17-fold
higher in BMP9 compared to minimal medium pellets
(P < 0.01) and 5.4-fold higher than TGFb1 pellets (P < 0.01)
(Fig. 2D). Of note, the greatest contrast between biochem-
ical content and gene expression measurements were for
ethanol-treated pellets, where gene expression values for
FIG. 2. Quantification of (A) sGAG (n = 6), (B) hydroxyproline content (n = 6), and gene expression levels of (C) ACAN
and (D) COL2A1 in chondroprogenitor pellet cultures (n = 4 for both genes). (E) Selected pellets were screened for
reactivity against antibodies to collagen (Col) types I and II and aggrecan (Agg). Scale bar equals 100mm. *P < 0.05,
**P < 0.01 versus control. ACAN, aggrecan; COL2A1, collagen type II. Color images are available online.
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FIG. 3. Cellular content of cultured
chondroprogenitor pellets cultured in mini-
mal chondrogenic medium, or the same
medium supplemented with various chon-
drogenic factors. (A) Cell number (n = 6)
was calculated by dividing total DNA con-
tent of papain digested pellets by the ap-
proximated weight of DNA in a single
bovine chondrocyte (calculated as 7.7 pg
[33]). Gene expression analysis using qPCR
of (B) PCNA and (C) NES in chon-
droprogenitor pellets (n = 4 for both genes).
*P < 0.05, **P < 0.01, ***P < 0.001 versus
control. NES, nestin; PCNA, proliferating
cell nuclear antigen; qPCR, quantitative
polymerase chain reaction.
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ACAN and COL2A1 were among the highest, while the
content values for proteoglycan (sGAG) and collagen (hy-
droxyproline) normalized to DNA were the lowest.
Immunohistochemical labeling of sections from pellets
cultured in minimal chondrogenic medium, or supple-
mented with TGFb1, BMP9, db-cAMP, or ethanol, against
antibodies labeling collagen types I and II, and aggrecan
illustrated not only the differences in relative amount of
protein deposited in the extracellular matrix of pellets but
also their differential localization (Fig. 2E). BMP9-treated
pellets displayed labeling for collagen type II and aggrecan
throughout the full depth of the pellet, whereas TGFb1-
treated pellets had higher collagen type I labeling through-
out the pellet with aggrecan labeling concentrated at the
pellet periphery as predicted from toluidine blue staining
(Fig. 1).
The DNA content of chondroprogenitor pellets, converted
to cell number, had two interesting features; first, BMP9
pellets exhibited the smallest average increase in cell
number from the starting count of 5 · 105 cells (26%), this
was 2.6-fold less than average cell counts for pellets cul-
tured in minimal medium (P < 0.01). Second, CNP, CCl, and
ethanol-treated pellets exhibited significant increases in cell
number when compared to pellets cultured in minimal me-
dium alone (P < 0.01) (Fig. 3A). Gene expression analysis
using primers for proliferating cell nuclear antigen (PCNA)
correlated with DNA measurements showing increased cell
number most notably in ethanol-treated pellets (P < 0.01)
(Fig. 3B). qPCR analysis also showed that nestin (NES), a
marker for MSCs, was significantly increased in ethanol
treated pellets only compared to pellets in minimal chon-
drogenic medium. Analysis of the relationship between
DNA and proteoglycan content of pellets showed a strong
negative correlation (r = -0.88, P < 0.001) between the two
variables with sGAG content decreasing with increasing
DNA content.
Titration of BMP9 growth factor to determine the opti-
mum concentration for articular chondroprogenitor differ-
entiation was examined in the range of 0–200 ng/mL of
growth factor using gene expression analysis of ACAN,
COL2A1, and collagen type X (COL10A1) of cells grown in
monolayer (Fig. 4). These data show that 100 ng/mL BMP9
was the optimum concentration for chondrogenic induction
of progenitors, ACAN and COL2A1 gene expression was
highest at this concentration (P < 0.001), whereas COL10A1
gene expression was greatest using BMP9 at 200 ng/mL.
While COL10A1 levels at 100 ng/mL BMP9 also induced a
significant increase, they were 7-fold less than using the
highest BMP9 concentration (1.4 · 10-3 – 1 · 10-4 vs.
9.7 · 10-3 – 4 · 10-4); in absolute terms, the expression level
of COL10A1 was *450-fold less than COL2A1 gene ex-
pression levels (0.68 – 0.01) at the same concentration of
BMP9 (100 ng/mL).
Developmental analysis of chondrogenesis has revealed
that extracellular matrix accumulation occurs in a phasic
manner. To examine if this was the case with BMP9-treated
chondroprogenitors, we measured the change in gene ex-
pression of ACAN, COL2A1, and COL10A1 in chon-
droprogenitor pellets over a period of 14 days. Visual
observation of pellet growth in BMP9 supplemented mini-
mal medium indicated that there was rapid growth over the
first 7–10 days beyond which point any increase in size was
imperceptible (data not shown). Gene expression data col-
lected over a 14-day period and normalized to pellets grown
in minimal chondrogenic medium (Fig. 5A) showed that
ACAN gene expression was maximal between days 2 and 4
and fell for the remaining period of analysis (day 0
0.35 – 0.07, day 3 9.48 – 2.02, and day 7 0.93 – 0.22). Si-
milarly, COL2A1 gene expression peaked between days 6
and 8 (day 0 0.09 – 0.008, day 7 3.66 – 0.53, day 9
0.87 – 0.15). The levels of COL10A1 gene transcription did
not rise significantly over 14 days and were maximal at day
7 (0.017 – 0.016) *215-fold less in absolute terms com-
pared to COL2A1 at day 7. We also examined markers of
cellular proliferation, PCNA, and MSC marker, NES, over
the same time period (Fig. 5B). We noted that the pattern of
gene expression, which was maximal between days 6 and 8,
was similar for both PCNA and NES.
Collagen deposition is a critical factor in the extracellular
matrix of cartilage tissue, and the manner in which the
FIG. 4. Determining the optimum BMP9 concentration for chondrogenic induction of immature articular chon-
droprogenitors. Progenitors (n = 4) grown in monolayer to near confluence (80%) were exposed to increasing concentration
of BMP9 (0–200 ng/mL) for 4 days and then assayed for gene expression using qPCR of (A) ACAN, (B) COL2A1, and
(C) COL10A1. *P < 0.05, **P < 0.01 versus control. COL10A1, collagen type X.
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collagen fibrils are aligned in the tissue affects their overall
contribution to the structure and function of tissue. Using
picrosirius red staining and polarized light microscopy
(PLM), we observed patterns of birefringence characteristic
of collagen fibril alignment in pellet cultures (Fig. 6A). The
most striking feature was the parallel alignment of thick
fibrils within pellets most notable in TGFb1-treated chon-
droprogenitors. At lower magnification, some evidence of
anisotropic collagen fibril organization could be observed in
pellets cultured with CCl, dexamethasone and BMP9. To
confirm the differential nature of the extracellular matrix
induced by different growth factors, atomic force micros-
copy (AFM) analysis was to determine the biophysical
characteristics of matrix deposited surrounding cells after
TGFb1 or BMP9 exposure in monolayer culture. These
experiments show that cell stiffness increases significantly
upon differentiation with both growth factors, but the
magnitude of increase is greater using TGFb1 (Fig. 7A).
Topographic maps of the matrix surrounding cells showed
more fibrous matrix in TGFb1-treated chondroprogenitors, a
feature much less prominent in matrix surrounding BMP9-
treated cells (Fig. 6B).
We reasoned that predifferentiated cells, that is, full-
depth chondrocytes isolated from intact immature cartilage,
and not requiring chondrogenesis before producing extra-
cellular matrix, would allow us to distinguish the different
functions of BMP9 on chondrocytes and cartilage. PLM
analysis of 21-day pellet cultures of 5 · 105 chondrocytes
FIG. 5. Quantitative analysis of gene expression in BMP9-treated chondroprogenitor pellets over 14 days. Chondrogenitor
pellets (n = 3) from 9 time points over 14 days were processed to isolate RNA and assayed using RT-qPCR gene expression
of (A) COL2A1, ACAN, and COL10A1 and (B) PCNA and NES. RT-qPCR, reverse transcription-quantitative polymerase
chain reaction.
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from immature cartilage treated with either TGFb1 or
BMP9 revealed profound differences in collagen and cel-
lular organization (Fig. 7). TGFb1-treated pellets displayed
characteristic parallel arrays of collagen alignment that ex-
tended from the periphery deep into the pellet, whereas
BMP9-treated pellets displayed an anisotropic organization
typically found in mature cartilage. Columnar arrays of
collagen fibrils perpendicular to the surface zone were
present in the deeper zones of BMP9-treated pellets and
chondrocytes were aligned in the direction of these fibrils
(arrowed in Fig. 7).
Discussion
The results of this study demonstrate that BMP9 is a
potent chondrogenic factor for immature articular cartilage-
derived chondroprogenitors. PLM also reveals that BMP9
is capable of inducing morphological changes either by
FIG. 6. Organization of collagen fibrils in differentiated chondroprogenitor pellets using polarized light microscopy.
(A) Pellets grown for 21 days were sectioned and stained with 1% PSR, washed, and mounted using DPX under cover-
slip. Scale bar equals 100 mm. (B) Atomic force microscopy analysis of the extracellular matrix deposited by chon-
droprogenitors cultured in monolayer undergoing differentiation following exposure to TGFb1 and BMP9. Representative
images show the fibrillar nature of the matrix produced by TGFb1-treated progenitors compared to BMP9 cells.
(C) Stiffness of the extracellular matrix surrounding chondroprogenitors grown in minimal chondrogenic medium or
supplemented with TGFb1 or BMP9 (n = 4, ***P < 0.001 vs. control). Representative images from two independent ex-
periments. PSR, picrosirius red. Color images are available online.
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stimulating deposition or reconfiguration of extracellular
matrices to produce an anisotropic structure that mirrors that
seen during postnatal maturation [30,44]. This study was
motivated by observations that articular cartilage-derived
chondroprogenitors are incompletely differentiated in pellet
culture when stimulated with TGFb1 [26]. In selecting
candidates for screening progenitors for enhanced chon-
drogenesis, we examined previous literature identifying
chondrogenic factors for embryonic chick limb mesen-
chyme. Our reasoning for this approach was that chon-
droprogenitors used in this study were derived from
newborn bovine cartilage whose structural organization is
isotropic [23,24], therefore, it was likely that they would be
more receptive to factors known to act on immature mes-
enchymal progenitors. Of particular note, we chose to in-
clude BMP9 (also known as growth and differentiation
factor-2, GDF2) based on studies showing that it could in-
duce chondrogenesis and phylogenetic data classifying it
and BMP10 into a separate group from other BMPs [45].
The concentrations of chondrogenic factors used in this
study were based on previously published data using iden-
tical or similar cells, an inherent limitation of this approach
therefore is the possibility that some factors may not be
present at their optimal concentration.
Following pellet culture for 21 days with candidate
chondrogenic factors, BMP9 was the most potent as viewed
by toluidine blue staining of sectioned tissue. Biochemical
and gene expression analyses confirmed histological obser-
vations of BMP9 enhancing differentiation of chon-
droprogenitors especially when compared to growth factors
TGFb1–3. Of particular note was immunohistochemical
data that showed the distribution of proteoglycan aggrecan,
and collagen type II antibody labeling was evenly spread in
BMP9 and db-cAMP compared to TGFb1-treated pellets.
We also observed a strong negative association between
cellular proliferation and sGAG deposition, where BMP9-
treated pellets did not show appreciable increase in cell
number from initial seeding. Without monitoring cell death
or proliferation directly, it is not possible to eliminate the
possibility that there was a balance between cell death and
proliferation within BMP9 pellets.
Analysis of gene expression of PCNA in BMP9-treated
pellets over a period of 14 days showed that there was a
peak in expression at day 7 and this coincided with a peak in
expression of nestin transcripts. Nestin is a class VI inter-
mediate filament protein that forms complex heterodimers
and heterotetramers, and there is strong evidence in MSCs
implicating it as a marker for multilineage progenitor cells
[46]. Nestin expression identifies MSC subpopulations es-
sential for hematopoietic stem cell expansion in the bone
marrow niche [47], and a study by Kang et al. examining the
role of IL6 in MSC cartilage differentiation showed that
nestin antibody labeling colocalizes with MSC marker
CD166 in macroscopically normal cartilage [48]. Therefore,
based on these indirect observations, we predict that a
subpopulation of chondroprogenitors are maintained within
the growing cartilage pellet and may act as a reserve pro-
genitor pool to stimulate further growth or repair [22,49,50].
Several reasons may explain why BMP9 is more effective
than the other factors used in this study. Pulse-chase ex-
periments using 35S-sulfate and 3H-proline by Hills et al.
showed that intact juvenile (1- to 3-month-old) bovine
cartilage explants treated with BMP9 increase their syn-
thesis of proteoglycan and collagen extracellular matrix
components and simultaneously exhibit reduced turnover of
labeled proteins [51]. Decreased proteolysis of extracellu-
lar matrix mediated by BMP9 could be accomplished
through suppression of protease activity by transcriptional
mechanisms or indirectly through upregulation of tissue
inhibitor of metalloproteinase gene transcription [52,53].
Conversely, the addition BMP9 (and BMP2) can overcome
the inhibitory effect of physiologically relevant levels of
proinflammatory cytokine IL1b on bone marrow-derived
MSC chondrogenesis by maintaining gene expression of
COL2A1, ACAN, and SOX9 [39].
BMP2 preferentially binds to activin receptor-like kinase-3
and -4 (ALK3/4) receptors and this probably accounts for
the differential induction of chondrogenesis in progenitors
when compared to BMP9, as BMP9 ligands signal through
ALK1/2 receptors as shown by inhibition of in vitro os-
teogenesis and in vivo ectopic bone formation following
transfection of dominant-negative ALK receptors into bone-
derived MSCs [54,55]. There is also evidence to suggest
that BMP signaling predominates in the earliest stages of
differentiation. Dedifferentiated articular chondrocytes cul-
tured as pellets initially display higher BMP4 expression,
FIG. 7. Organization of collagen fibrils in pellet cultures
of freshly isolated full depth immature chondrocytes. Pellets
composed of 1 · 105 cells each were cultured in standard
chondrogenic medium for 21 days with either TGFb1
(10 ng/mL) or BMP9 (100 ng/mL). Pellets were processed to
wax, sectioned, and stained with hemotoxylin and eosin
(upper panel), safranin-O (middle panel), and PSR (lower
panel). Scale bar equals 100 mm. PSR-stained sections were
visualized using polarized light microscopy and the bulk
orientation of collagen fibrils is shown by the arrows in each
image (lower panels). Representative images from three
independent experiments. Color images are available online.
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SMAD 1/5/8 phosphorylation, and SOX9 protein levels and
undergo faster redifferentiation when compared to bone
marrow-derived MSCs, highlighting the early role of BMPs
in chondrogenesis [56]. Furthermore, transgenic studies
conclude that TGFb growth factors are not essential for
prechondrogenic condensation formation; conditional abla-
tion of ALK5 using Dermo-Cre targeting mesenchymal
progenitors does not affect either condensation or cartilage
formation [57], indicating that stimulation of chondrogen-
esis through activation of SMAD 1/5/8 predominates in the
early stages of differentiation.
During postnatal growth and homeostasis, TGFb signal-
ing through ALK5 receptors act as an inhibitory stimulus on
chondrocyte terminal differentiation and the adoption of a
mineralizing phenotype in cells [58]. An age-associated
imbalance in the ratio of ALK5 to ALK1 seen in osteoar-
thritic cartilage is also further evidence for the develop-
mental and pathological context-dependent activities of
BMP and TGFb growth factors on chondrocytes [59].
Therefore, articular chondroprogenitors may be primed to
undergo rapid chondrogenic differentiation following
receptor-mediated SMAD 1/5/8 signaling and, in later
stages, postcondensation, TGFb-dependent SMAD 2/3 sig-
naling may predominate to promote homeostatic growth and
prevent mineralization in permanent chondrocytes.
PLM of cartilage pellets showed that for the most part,
collagen fibrils were organized in highly fibrillar, annular,
and concentric patterns. The exception were db-cAMP-
treated pellets, where very weak birefringence signal was
detected, indicating an unusual lack of fibril organization. In
BMP9-treated pellets, there was evidence of fibrils orga-
nized perpendicular to the surface, but the birefringence
signal was relatively weak (Fig. 6A, BMP9 inset). We hy-
pothesized that the incomplete morphogenic effects of
BMP9 on chondroprogenitors were due to the need for these
cells first to undergo differentiation. Therefore, we cultured
freshly isolated full-depth chondrocytes from immature
cartilage with TGFb1 and BMP9 for 21 days. BMP9-treated
chondrocytes produced a birefringence pattern of collagen
fibril alignment and organization indistinguishable from the
pattern found in mature adult cartilage, with a thin ring of
parallel fibers running across the peripheral boundary of the
pellet below, which were fibers in antiparallel orientation.
Chondrocytes in columnar organization and with enlarged
chondrons were clearly visible in safranin O-stained sec-
tions of BMP9-treated pellets. In contrast, TGFb1-treated
chondrocyte pellets produced a broad fibrillar ring of col-
lagen orientated parallel to the surface. AFM analysis of
chondroprogenitors differentiated with TGFb1 or BMP9
showed that TGFb1-induced matrix deposition was pre-
dominantly fibrillar and significantly stiffer compared to
BMP9-treated cells, which themselves produced a less fi-
brillar and more compliant matrix. Substrate compliance is
known to alter not only cell phenotype but also plays a role
in tissue development, where stiffer artificial matrices neg-
atively regulate tissue architecture and differentiation [60].
We have previously proposed that a transient genetic
program is activated to initiate postnatal maturation of ar-
ticular cartilage [30–32], although it remains to be seen
whether elements of this program have been invoked by
BMP9 treatment. Also, in this study, we used progenitors
and chondrocytes from immature cartilage and whether
progenitors and chondrocytes from older structurally mature
cartilage are similarly receptive to BMP9-induced chon-
drogenesis or morphogenic cues also remains to be tested.
Understanding how articular cartilage undergoes the post-
natal transition from isotropically organized immature car-
tilage to anisotropically mature cartilage is critical for tissue
engineering, regeneration, and repair strategies. Whether
chondroprogenitor proliferation at the joint surface initiates
a process of appositional growth generating trailing pillars
or stacks of daughter cells [24,61] or cellular hypertrophy,
matrix deposition, and reorganization of chondrocytes un-
derlies the growth and maturation of the tissue [62] are is-
sues that need to be resolved. Our finding showing for the
first time that postnatal maturation can be rapidly recapitu-
lated in vitro may help to shed light on these competing
hypotheses.
In conclusion, BMP9 is a potent chondrogenic factor for
immature chondroprogenitors and additionally provides
morphogenic cues for progenitors and differentiated chon-
drocytes to generate adult-like anisotropic organization. The
identification of BMP9 opens up the possibility of using
allogeneic culture-expanded progenitors for in vitro pro-
duction of fully differentiated and functional implants for
repair of localized cartilage lesions.
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